Evaluating patient satisfaction with home immunotherapy for cancer
Official title: A French Non-interventional Prospective Multicenter Study Evaluating Quality of Care Perception of Cancer Patients Treated by Immunotherapy at Home - SATISFACT-HOME
Run by Bristol-Myers Squibb · NCT06163053 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is trying to see if people with advanced solid tumors are happier with their cancer immunotherapy when they receive it at home instead of in a hospital.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Drugs / interventions | immunotherapy |
| Locations | 3 sites (Chambéry and 2 other locations) |
| Trial ID | NCT06163053 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with advanced solid tumors receiving immunotherapy who have been approved for home treatment.
✕Probably not a fit
Patients who are under guardianship or participating in other interventional studies for cancer treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study in France aims to assess changes in patient satisfaction among individuals with solid tumors who have transitioned from receiving immunotherapy in a hospital outpatient setting to receiving it at home. Participants will include adults who have been treated with immune checkpoint inhibitors for advanced solid tumors and have been deemed eligible for home treatment by their oncology specialists. The study will collect data on patient experiences and satisfaction levels to understand the impact of this transition on their care.
Why it matters
Potential benefit: If successful, this study could enhance the quality of life for cancer patients by improving their treatment experience at home.
How similar studies have gone: While this approach is observational, similar studies evaluating patient satisfaction with home-based treatments have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female ≥ 18 years old * Participants whose oncology specialist has already initiated treatment with immune checkpoint inhibitors (ICIs) in the outpatient hospital setting for an advanced solid tumor (as monotherapy or in combination) or as adjuvant therapy, in an indication approved and reimbursed in France * Participants whose oncology specialist has independently of the study defined their eligibility for hospital at home (HAH) before contacting the HAH unit for final admission * Participants who provide oral informed consent to participate in the study Exclusion Criteria: * Participants who have expressed an opposition to their data collection * Participants under guardianship * Participants taking part in an interventional study for cancer treatment with at least one ICI as an investigational drug
Where it's running
-
CH Metropole Savoie
Chambéry, France Recruiting -
CH Francois Quesnay
Mantes-La-Jolie, France Recruiting -
CH de Pau
Pau, France Recruiting
Study contacts
- Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BA1203 in advanced solid tumors: safety and early signs of activity
This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
REC-7735 for PIK3CA-H1047R-mutant solid tumors
This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.
-
Preferences of physicians and patients for cell therapies in advanced solid tumors
This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.
-
HP007 monotherapy for relapsed or advanced solid tumors
This study tests HP007 as a standalone treatment in adults with hard-to-treat solid tumors to see if it is safe and tolerable and to look for early signs of activity.
-
ONO-7429 in advanced or recurrent solid tumors
This small early-phase study tests whether ONO-7429 is tolerable and safe in adults with unresectable advanced or recurrent solid tumors who have tried other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.